Travere Therapeutics Provides Regulatory Updates on its Development Programs

SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today provided regulatory updates for its sparsentan programs in IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS), as well as its pegtibatinase program for classical homocystinuria (HCU).

Read the full press release >
Eric Dube Ernst Young

Eric Dube Named EY Entrepreneur of the Year 2022 Pacific Southwest Award Winner

Ernst & Young today announced that our CEO Eric Dube has been named an Entrepreneur of the Year 2022 Pacific Southwest Award winner! This prestigious award recognizes exemplary leaders who lift up their employees and their communities and are focused on creating a better world for all. A panel of independent judges selected 13 winners out of the 40 finalists who were eligible for the award.

Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congress

SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced presentations including baseline characteristics for patients enrolled in the ongoing pivotal Phase 3 PROTECT and DUPLEX studies of sparsentan in IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS), respectively, at the 59th European Renal Association (ERA) Congress. The Company and its collaborators will also present nonclinical data examining the renal protective effects of sparsentan compared to controls. ERA is being held live in Paris, France, and virtually May 19-22, 2022.

Read the full press release >

Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy

SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of its New Drug Application (NDA) under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy (IgAN).

Read the full press release >

Travere Therapeutics Reports First Quarter 2022 Financial Results

SAN DIEGO, May 5, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2022 financial results and provided a corporate update.

Read the full press release >
Eric Dube The Medicine Maker 2022 Power List

Eric Dube Named to The Medicine Maker’s ‘The Power List 2022’

Monday, May 2, 2022 -- Congratulations to our president and CEO, Eric Dube, Ph.D., for being named to The Medicine Maker's ‘The Power List 2022’. Eric drives innovation by championing “continued, relentless attention to understanding the unique experiences of all patients and bringing those perspectives into everything we do.” Eric explains his philosophy on the importance of integrating the patient and caregiver voice early and often in the drug development process at themedicinemaker.com

Travere Therapeutics Announces Plan for Chief Financial Officer Transition

SAN DIEGO , April 20, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that its chief financial officer Laura Clague, CPA, will retire after serving in this role for the past seven years. Ms. Clague will step down from the CFO position in August 2022 and will remain employed by the Company in an advisory capacity into 2023 to facilitate a smooth transition. Chris Cline, CFA, the Company’s current senior vice president of investor relations and corporate communications and a member of the senior leadership team, has been named Ms. Clague’s successor as chief financial officer, to be effective in August 2022.

Read the full press release >
Jula Inrig M.D.

Jula Inrig named to Women We Admire’s ‘Top 50 Women Leaders of Los Angeles’ for 2022

Monday, April 18, 2022 -- Our leaders’ reach extends into the communities in which they live and far beyond. Congratulations to our chief medical officer Jula Inrig, M.D., for being named to Women We Admire’s 'Top 50 Women Leaders of Los Angeles for 2022.’ Dr. Inrig has spent most of her career focused on advocating for patients with medical conditions that are often overlooked. Her commitment to delivering innovative therapies to those living with rare disease inspires us all.

Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 43rd Annual Meeting and the Genetic Metabolic Dieticians International Conference 2022

SAN DIEGO , April 06, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company will present data from the ongoing Phase 1/2 COMPOSE Study of pegtibatinase, a novel investigational enzyme replacement therapy being evaluated for the treatment of classical homocystinuria (HCU).

Read the full press release >

Travere Therapeutics Submits New Drug Application for Sparsentan for the Treatment of IgA Nephropathy

SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy (IgAN).

Read the full press release >